The entry fatty acids C7 to C20 contains three individual active substances – fatty acids C7-C18 and C18 unsaturated potassium salts, capric acid and caprylic acid. Two applications for the renewal of the approval of the active substance fatty acids C7-C18 and C18 unsaturated potassium salts were submitted on 18 and 31 August 2016, respectively, one application for the renewal of the approval of the active substance capric acid was submitted on 31 August 2016 and one application for the renewal of the approval of the active substance caprylic acid was submitted on 31 August 2016. The rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 10 October 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. The rapporteur Member State submitted the draft renewal assessment reports to the Authority, on 14 July 2021 for fatty acids C7-C18 and C18 unsaturated potassium salts and on 27 April 2021 for both capric acid and caprylic acid. The Authority conducted public consultations on reports for fatty acids C7-C18 and C18 unsaturated potassium salts between 31 March and 30 May 2023 and for capric acid and caprylic acid both between 16 March and 15 May 2023. On 26 October 2023, the Authority requested additional information for all three active substances for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 24 and 27 November 2023, respectively, for fatty acids C7-C18 and C18 unsaturated potassium salts and on 27 November 2023 for both capric acid and caprylic acid within the deadline given. On 30 June 2023, the rapporteur Member State submitted the draft renewal assessment reports to the Authority. The Authority estimates that it will be able to finalise all three conclusions for fatty acids C7 to C20 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.
Recital 28, Regulation (EU) 2026/2348
In force
- celex=32012R0844